Development of a generalized, quantitative physicochemical model of CYP3A4 inhibition for use in early drug discovery

Pharmaceutical Research

Volumn 18, Issue 5, 2001, Pages 652-655

  Riley, R J ^a   Parker, A J ^a   Trigg, S ^a   Manners, C N ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

CYP3A4; IC50; Lipophilicity; Quantitative physico chemical model

Indexed keywords

BROMOCRIPTINE; CHLOROQUINE; CIMETIDINE; CYTOCHROME P450 3A4; DIHYDROERGOTAMINE; DILTIAZEM; ECONAZOLE; ERYTHROMYCIN; GLIPIZIDE; HEME; IMIDAZOLE DERIVATIVE; KETOCONAZOLE; METYRAPONE; MICONAZOLE; N DEMETHYLASE; NIFEDIPINE; OMEPRAZOLE; PIROXICAM; PROPICONAZOLE; PYRIDINE DERIVATIVE; RECOMBINANT ENZYME; SULFAMETHIZOLE; TAZANOLAST; THIOPERAMIDE; TIMOPRAZOLE; TRIADIMEFON; TRIAZOLE; TROLEANDOMYCIN; UNINDEXED DRUG; VERAPAMIL;

ARTICLE; DRUG POTENCY; ENZYME INHIBITION; LIPOPHILICITY; PHYSICAL CHEMISTRY; PKA; PRIORITY JOURNAL; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION;

ALGORITHMS; CHEMISTRY, PHYSICAL; CYTOCHROME P-450 CYP1A1; ENZYME INHIBITORS; HUMANS; INDICATORS AND REAGENTS; MODELS, CHEMICAL; PYRIDINES; RECOMBINANT PROTEINS;

EID: 0034950245     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011085411050     Document Type: Article

References (20)

1. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
2. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
3. Inhibition and induction of cytochrome P 450 and the clinical implications
4. Terfenadine-ketoconazole interaction: Pharmacokinetic and electrocardiographic consequences
5. Cisapride and torsades de pointes
6. Drug-drug interactions of new active substances: Mibefradil example
7. Understanding consequences of concurrent therapies
8. Structure-function of cytochromes P450 and flavin-containing monooxygenases: Implications for drug metabolism
9. Metabolism of the new immunosuppressor cyclosporin G by human liver cytochromes P450
10. Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P450- 3A4 inhibitors
11. Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: Assessment of human CYP inhibition potential
12. Rapid characterization of the major drug-metabolizing human hepatic cytochrome P-450 enzymes expressed in Escherichia coli
13. 14C]erythromycin
14. 50) of an enzymatic reaction
15. Cyclosporin A drug interactions: Screening for inducers and inhibitors of cytochrome P450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes
16. CYP3A4 drug interactions: Correlation of 10 in vitro probe substrates
17. Human cytochrome P-450 3A4: In vitro drug-drug interaction patterns are substrate-dependent
18. Human cytochrome P450s: Selectivity and measurement in vivo
19. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
20. Drug metabolism: Towards the next millenium